Trastuzumab (T) and everolimus (E) pharmacokinetics (PK) in HER2 positive (+) primary breast cancer (BC) patients (pts): Unicancer RADHER trial results.
Guillemette Bernadou
No relevant relationships to disclose
Keyvan Rezai
No relevant relationships to disclose
Jean-Louis Merlin
No relevant relationships to disclose
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; Roche; SERVIER
Research Funding - Novartis
Francois Lokiec
No relevant relationships to disclose
Thomas Denis Bachelot
Consultant or Advisory Role - Novartis; Roche
Honoraria - Novartis; Roche
Research Funding - Novartis; Roche
Suzette Delaloge
No relevant relationships to disclose
Veronique Dieras
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Marta Jimenez
Research Funding - Novartis; Roche
David Ternant
No relevant relationships to disclose
Gilles Paintaud
No relevant relationships to disclose